Fr | Ar

Mr. Jad CHEMALI (EL)

Faculty of Medicine
Faculty of Science
Faculty of Science - South Lebanon Branch

Lecturer

(+961) 1 421 000 ext 6820 jad.chemali@usj.edu.lb

Dr. Jad N. Chémali is a medical researcher, specializing in cancer treatment. Originally from Lebanon, he moved to France at a young age to pursue his education, finding a nurturing environment for his scientific aspirations. Academic Background Bachelor’s Degree in Biochemistry Molecular Biology from Paul Sabatier University, Toulouse III, France. Master’s Degree in Biochemistry Biotechnology from Paul Sabatier University, Toulouse III, France. Master 2 in Chemistry for Health, specializing in gene therapy drug design, from Paul Sabatier University, Toulouse III, the National Polytechnic Institute of Toulouse, France. PhD in Chemistry-Biology-Health, focusing on the synthesis of anticancer molecules for photodynamic therapy, from Paul Sabatier University, Toulouse III, France. Career Contributions After earning his PhD, Dr. Chémali conducted postdoctoral research at the IMRCP laboratory (CNRS, UMR 5623) in Toulouse for two years. He then returned to Lebanon to continue his cancer research, with a particular focus on drug repurposing. This innovative approach seeks to identify existing drugs approved for other diseases that could be effective against cancer, thereby reducing the costs time needed to develop new treatments. Research Teaching Activities Alongside his research, Dr. Chémali is a dedicated educator at Saint Joseph University of Beirut (USJ), teaching at both the Faculty of Medicine the Faculty of Sciences. He currently serves as the director of the Cancer Carcinogen Agents Laboratory at the USJ Faculty of Medicine. His research areas include: Personalized Cancer Treatments: Developing therapies tailored to the individual characteristics of each patient. Carcinogenic Agents: Studying their impact on the early onset of certain cancers in Lebanon. Cancer Root Causes: Investigating potentially unknown phenomena that may contribute to cancer. Vision and Impact Dr. Chémali is passionately committed to the fight against cancer, continually seeking innovative and effective solutions. His holistic approach and dedication to exploring new therapeutic options underscore his significant contributions to cancer research.


DegreesUniversityCountryYear
Chemistry-Biology-HealthUniversité Paul-Sabatier (ToulouseIII)France2013
Chemistry- Biologie -HealthUniversité Paul-Sabatier (ToulouseIII)France2008
Biotechnology and BiochemistryUniversité Paul-Sabatier (ToulouseIII)France2007
Biochemistry and Molecular BiologyUniversité Paul-Sabatier (ToulouseIII)France2006

Metabolic Biochemistry Structural Biochemistry Chemical Contaminants Cancer Reproductive Biology Cell Biology Nutrition Metabolism of the Healthy Human Biochemistry of Cancer Cells Drug Repurposing in Oncology

Experience in University Teaching Outside USJCountryInstitutionStart DateEnd Date
Courses: “General Biology”, “Human Physiology” and “Food Cancer Risks”LebanonAmerican University College of Technology (AUT)26/09/201620/06/2017
Teaching Assistant: Photodynamic Therapy for CancerFranceUniversité Paul-Sabatier (ToulouseIII)01/02/201301/03/2013
Teaching Assistant: Applications of Gene TherapyFranceUniversité Paul-Sabatier (ToulouseIII)01/10/201201/11/2012

Professional ExperienceOrganizationStart dateEnd date
Medical researcherUSJ01/10/201601/01/2024
Postdoctoral Training: Medical Molecular Biology: Saint Joseph University, Beirut, LebanonUSJ01/10/201501/10/2016
Temporary researcherIMRCP Laboratory Toulouse III01/10/201201/10/2014

Medecine and Health

The laboratory focuses on developing innovative strategies to combat cancer. This includes the repurposing of FDA-approved drugs to find effective combinations against various forms of cancer. A personalized medicine approach is also implemented to determine the best treatment for each patient using biopsies ex vivo tests. Additionally, the laboratory is interested in studying the risk of contaminants causing cancer in the Lebanese population, particularly aflatoxin B1. There is also a focus on studying arsenic its impact on the risk of breast ovarian cancer in women carrying BRCA1 BRCA2 mutations. The laboratory is also interested in studying other causes of cancer to identify the true triggering factors.

-Synthesis, physico-chemical properties, cellular penetration photodynamic antiproliferative activity on MCF7 breast cancer cell line of new rose bengal-estradiol conjugates. Jad Chemaly, Patricia Vicendo, Naram El-Akra Jean-Pierre Souchard. Photodiagnosis Photodynamic Therapy. DOI: 10.1016/j.pdpdt.2017.01.122. -Role of intercalation redox potential in DNA photosensitization by ruthenium (II) polypyridyl complexes: assessment using DNA repair protein tests. Etienne Gicquel, JeanPierre Souchard, Fay Magnuson, Jad Chemali, Patrick Calsou Patricia Vicendo. Photochem. Photobiol. Sci., DOI: 10.1039 / C3PP50070E. -Tratrat C, Petrou A, Fesatidou M, Haroun M, Athina G, Venugopala K, Sreeharsha N Chemali Jad. 5-Membered Heterocyclic Compounds as Antiviral Agents. Curr Top Med Chem. 202323(7):520-538. doi: 10.2174/1568026623666230325153927. PMID: 37254567. Jad Chemaly, Patricia Vicendo, Naram El-Akra Jean-Pierre Souchard, “Synthesis, physico-chemical properties, cellular penetration photodynamic antiproliferative activity on MCF7 breast cancer cell line of new rose bengal-estradiol conjugates”. Joint Congress of the French and Italian Photochemists and Photobiologists. Bari, Italy, September 19-22, 2016. Jad Chemali, El-Akra Naram, Vicendo Patricia, Souchard Jean Pierre, “Synthesis, physicochemical properties, cellular penetration and photodynamic antiproliferative activity on MCF7 breast cancer cell line of new rose bengal-estradiol conjugates”. International symposium on photodynamic therapy in clinical practice. October 24-28, 2016, Nancy, France. Jad Chemali, Naram El-Akra, Ariel Noirot, Jean-Charles Faye, Patricia Vicendo, and Jean Pierre Souchard, “Photocytotoxic active vectorization probes for photodynamic therapy by targeting the Estradiol nuclear receptor”. December 12-13, 2012. Toulouse, France.